Idiopathic pulmonary fibrosis is a risk factor for cardiovascular disease: potential role of KL-6 and systemic inflammation by Mohamed F. AbdelGhany, Waleed GamalEldin Khaleel, Asmaa Omar Ahmed, Ahmad BaheyElden Ahmed, Lamees M. Bakkar

Subjects: Get full text

Contemporary Trends in Pulsed Field Ablation for Cardiac Arrhythmias by Hagai Yavin, Mark Prasad, Jonathan Gordon, Tolga Aksu, Henry D. Huang

Subjects: Get full text

Extraction of cellulose from Forsskaolea tenacissima L through alkalization and bleaching processes: Characterization, and application to the adsorption of hazardous cationic dyes... by Afnan Altwala, Mahjoub Jabli

Subjects: Get full text

Interatrial Block and Electrocardiographic Markers of Repolarization in Patients Hospitalized with COVID-19: Classical and Bayesian Analysis by Rengin CETIN GUVENC, Ali Kaan GUREN, Busra ENGUR, Selin CELİK, Refik DEMIRTUNC

Subjects: Get full text

Defibrillation pad placement accuracy among Advanced Life Support instructors: A manikin-based observational study examining experience, self-evaluation, and actual performance by Dennie Wulterkens, Freek Coumou, Cornelis Slagt, Reinier A. Waalewijn, Lars Mommers

Subjects: Get full text

Safety and effectiveness of appropriately and inappropriately dosed rivaroxaban or apixaban versus warfarin in patients with atrial fibrillation: a cohort study with nested case–control analyses from UK primary care by Luis Alberto García Rodríguez, Pareen Vora, Luke Roberts, Gunnar Brobert, Samuel Fatoba, María Eugenia Sáez, Antonio González-Pérez

“…Objectives To investigate effects of appropriately and inappropriately dosed apixaban/rivaroxaban versus warfarin on effectiveness and safety outcomes in patients with non-valvular atrial fibrillation (NVAF).Design Cohort study with nested case–control analyses using primary care electronic health records (IQVIA Medical Research Data UK database).Setting UK primary care.Participants Patients aged ≥18 years with NVAF newly prescribed apixaban (N=14 701), rivaroxaban (N=14 288) or warfarin (N=16 175) between 1 January 2012 and 30 June 2018, and followed up to 31 December 2018.Primary and secondary outcome measures Incident cases of ischaemic stroke/systemic embolism (IS/SE) and intracranial bleeding (ICB). …”
Get full text

Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database by Gregory Y H Lip, Sally Lee, Brigitta U Monz, Andreas Clemens, Martina Brueckmann

“…Objective Three oral anticoagulants have reported study results for stroke prevention in patients with atrial fibrillation (AF) (dabigatran etexilate, rivaroxaban and apixaban); all demonstrated superiority or non-inferiority compared with warfarin (RE-LY, ARISTOTLE and ROCKET-AF). …”
Get full text

The triphenylmethane dye brilliant blue G is only moderately effective at inhibiting amyloid formation by human amylin or at disaggregating amylin amyloid fibrils, but interferes with amyloid assays; Implications for inhibitor design. by Rehana Akter, Alexander Zhyvoloup, Bingqian Zheng, Surita R Bhatia, Daniel P Raleigh

“…BBG also remodels preformed h-amylin amyloid fibrils if added in excess, however BBG has no significant effect on h-amylin induced toxicity towards cultured β-cells or cultured CHO-T cells except at high concentrations. …”
Get full text

Deep neuromuscular blockade during radiofrequency catheter ablation under general anesthesia reduces the prevalence of atrial fibrillation recurrence when compared to moderate neuromuscular blockade: A randomized controlled trial by Eun Jung Oh, Jae-Geum Shim, Suyong Jeon, Eun Ah Cho, Sung Hyun Lee, Taeho Jeong, Jin Hee Ahn

Get full text

Hydrogen decreases susceptibility to AngII-induced atrial fibrillation and atrial fibrosis via the NOX4/ROS/NLRP3 and TGF-β1/Smad2/3 signaling pathways by Binmei Zhang, Jingxiu Hou, Jiaren Liu, Junhui He, Yunan Gao, Guangnan Li, Tianjiao Ma, Xin Lv, Li Dong, Wei Yang

Get full text

Hydrogen decreases susceptibility to AngII-induced atrial fibrillation and atrial fibrosis via the NOX4/ROS/NLRP3 and TGF-β1/Smad2/3 signaling pathways. by Binmei Zhang, Jingxiu Hou, Jiaren Liu, Junhui He, Yunan Gao, Guangnan Li, Tianjiao Ma, Xin Lv, Li Dong, Wei Yang

“…Atrial fibrillation (AF) represents the commonly occurring cardiac arrhythmia and the main factor leading to stroke and heart failure. …”
Get full text

Center-Related Variation in Hospitalization Cost for Patients Undergoing Percutaneous Left Atrial Appendage Occlusion by Shivaraj Patil, MD, Chaitanya Rojulpote, MD, Abhijit Bhattaru, BS, Avica Atri, MD, Krishna Vamsi Rojulpote, BS, Ola Khraisha, MD, Viha Atri, MD, William Frick, MD, Tarek Nafee, MD, Kishore Harjai, MD, Sumeet Mainigi, MD, Chien-Jung Lin, PhD, MD

Subjects: Get full text

Incident prescriptions for common cardiovascular medications: comparison of recent versus pre-2020 medication adherence and discontinuation in three universal health care systems by Candace D. McNaughton, Peter C. Austin, Cynthia A. Jackevicius, Anna Chu, Jessalyn K. Holodinsky, Michael D. Hill, Colleen M. Norris, Mukesh Kumar, Noreen Kamal, Douglas S. Lee, Nadia Khan, Manav V. Vyas, Raed A. Joundi, Moira K. Kapral, Amy Y. X. Yu

Subjects: Get full text

Effects of Eleclazine (GS6615) on the proarrhythmic electrophysiological changes induced by myocardial stretch by Francisco J. Chorro, Francisco J. Chorro, Francisco J. Chorro, Luis Such-Miquel, Luis Such-Miquel, Samuel Cuñat, Oscar Arias-Mutis, Oscar Arias-Mutis, Patricia Genovés, Patricia Genovés, Manuel Zarzoso, Manuel Zarzoso, Antonio Alberola, Antonio Alberola, Luis Such-Belenguer, Luis Such-Belenguer, Irene Del Canto, Irene Del Canto

Subjects: Get full text

The influence of COVID-19 pandemic on secondary prevention in non-COVID patients with cardioembolic stroke by Lučić-Prokin Aleksandra L., Bogdanović Milan M., Pustahija Tatjana L., Stamenković Marija S.

Subjects: Get full text

Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis by Xiaoyan Liang, Jianghong Dai, Feifei Wang

Subjects: “…Atrial fibrillation…”
Get full text

Comparative safety and effectiveness of oral anticoagulants in key subgroups of patients with non-valvular atrial fibrillation and at high risk of gastrointestinal bleeding: A cohort study based on the French National Health Data System (SNDS). by Gregory Y H Lip, Robert Benamouzig, Anne-Céline Martin, Giancarlo Pesce, Gaelle Gusto, Nadia Quignot, Artak Khachatryan, Feng Dai, Fouad Sedjelmaci, Jose Chaves, Rupesh Subash, Ruth Mokgokong

“…<h4>Background</h4>Risk factors and comorbidities can complicate management of non-valvular atrial fibrillation. We describe and compare real-world safety and effectiveness of direct oral anticoagulants (DOACs; apixaban, rivaroxaban, dabigatran) and vitamin K antagonists (VKAs) in subgroups of patients with non-valvular atrial fibrillation at high risk for gastrointestinal (GI) bleeding, utilizing data from a national quasi-exhaustive French database.…”
Get full text

Clinical Usefulness of Atrioventricular Coupling in Cardiovascular Disease by Yang Lan, Li Zhenyi, Chen Ya, Chen Anni, Wang Xinqi, Jin Lin, Li Zhaojun

Subjects: “…|echocardiography|atrioventricular coupling|left atrioventricular coupling index|heart failure|atrial fibrillation…”
Get full text

Case Report: A rare case of Noonan syndrome with multiple lentigines manifesting as cardiac enlargement by Linghua Fan, Jie Jiang, Yan Zhang, Xiaoning Han, Wenhui Ding, Xiaodi Xue, Yimeng Jiang

Subjects: Get full text

Impact of Silent Cerebral Embolism during and after Left Atrial Appendage Occlusion on Long‐Term Cognitive Function by Kexin Wang, Zhe Wang, Caiyi Jin, Mingjia Xu, Mingfang Li, Hailei Liu, Zidun Wang, Hongwu Chen, Weizhu Ju, Minglong Chen

Subjects: Get full text